Skip to main navigation Skip to search Skip to main content

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients

  • Hazel Allardyce* (Corresponding Author)
  • , Heather Lanz
  • , Benjamin D. Lawrence
  • , Thomas Owen Crawford
  • , Charlotte J. Sumner
  • , Simon H Parson* (Corresponding Author)
  • *Corresponding author for this work
  • University of Aberdeen
  • Johns Hopkins University

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)

Abstract

Severe spinal muscular atrophy (SMA) is a life-limiting neurodegenerative disease of infancy and early childhood, caused by reduced expression of the ubiquitous survival motor neuron protein (SMN). While current therapies aim to increase SMN levels and preserve motor neurons, significant deficits remain in treated patients and non-neuronal manifestations of SMN deficiency are underexplored. Vascular abnormalities including intrinsic endothelial cell dysfunction, altered vessel morphology, and altered vascular distribution have been reported in preclinical SMA models. Here, we characterised vascular architecture and blood-spinal cord barrier (BSCB) morphology and integrity in post-mortem spinal cord samples from severe SMA patients compared with unaffected controls. Von Willebrand Factor (vWF), a marker of endothelial cell health, was reduced within individual vascular endothelial cells, and associated with ultrastructural endothelial cell oedema, vacuolisation and compromised endothelial integrity. Ultrastructural damage extended to other components of the BSCB as evidenced by extravascular leakage of fibrinogen into the neural parenchyma and microglial activation consistent with a neuroinflammatory environment. Together, these findings suggest that vascular defects with associated dysfunction of the BSCB are present in the spinal cord of infants with severe SMA. This work adds to a growing body of evidence linking microvascular dysfunction to neurodegeneration in human neurodegenerative diseases. Further studies are warranted to define the contribution of vascular dysfunction to SMA pathogenesis and to assess whether current therapies adequately address this aspect of the disease.
Original languageEnglish
Article number65
Number of pages14
JournalActa Neuropathologica Communications
Volume14
Issue number1
Early online date15 Feb 2026
DOIs
Publication statusPublished - 24 Mar 2026

Bibliographical note

We would like to acknowledge Patrice Carr at the Department of Neurology, Johns Hopkins University School of Medicine for sample identification, organisation and shipment to the University of Aberdeen. We also wish to thank Professor Peter Dockery, University of Galway, for his advice on the design and application of stereological techniques, and the Microscopy and Histology Core Facility members, Gillian Milne, Lucy Wight and Debbie Wilkinson at the University of Aberdeen.

Data Availability Statement

The datasets generated during the current study available from the corresponding author on reasonable request.

Funding

This work was supported by funding from the SMA Foundation and the NIH (R35 NS122306) to CJS, and an Anatomical Society PhD Studentship (RG14940-10) and University of Aberdeen Development Trust grant to SHP and HA.

FundersFunder number
Spinal Muscular Atrophy FoundationR35 NS122306
Anatomical SocietyRG14940-10

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • von Willebrand Factor
    • Endothelial cell
    • BSCB
    • Astrocytes
    • Pericytes
    • Microglia

    Fingerprint

    Dive into the research topics of 'Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients'. Together they form a unique fingerprint.

    Cite this